Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors

NCT06299163 is registered in ClinicalTrials.gov with Numab Therapeutics AG as lead sponsor.

NCT NCT06299163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
Lead sponsor
Numab Therapeutics AG
Phase
Phase 1
Overall status
Terminated
Start date
May 1, 2024
Completion date
April 18, 2025
Enrollment
11 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma - gastroesophageal junction (gej), adenocarcinoma of lung, adenocarcinoma of the stomach, endometrial cancer, fallopian tube carcinoma, leiomyosarcoma, liposarcoma, melanoma, malignant, mesothelioma, malignant, ovarian carcinoma, peritoneal carcinoma, renal cell carcinoma, triple negative breast cancer